TD Cowen analyst Dan Brennan lowered the firm’s price target on 10x Genomics (TXG) to $11 from $15 and keeps a Hold rating on the shares. The weak, uncertain outlook for U.S. A&G customers that account for 40%-50% of sales led management to pull annual guidance, but the “good news” is that 10x Genomics is aggressively cutting costs, the analyst tells investors in a post-earnings note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics price target lowered to $9 from $12 at JPMorgan
- 10x Genomics: Navigating Uncertainty Amidst Regional Variations and Budget Constraints
- 10x Genomics: Hold Rating Amidst Research Funding Uncertainty and Market Risks
- 10x Genomics Reports Q1 2025 Financial Results
- 10x Genomics: Hold Rating Amid Uncertain Outlook and Strategic Cost Management